Skip to main content
. 2020 Apr 10;10:6220. doi: 10.1038/s41598-020-63060-1

Table 2.

Univariate and multivariate analysis of prognostic factors for progression-free survival of metastatic RCC patients treated by nivolumab monotherapy.

Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Age (<66 vs. ≥66 years) 1.08 0.35–3.35 0.901
Gender (Male vs. Female) 2.18 0.64–7.50 0.216
WHO/ISUP grade (1, 2 vs. 3, 4) 4.80 1.27–18.10 0.020 4.63 1.10–19.45 0.036
Coagulative necrosis (absence vs. presence) 1.39 0.44–4.42 0.576

MSKCC risk classification

(Good/Intermediate vs. Poor)

8.83 2.47–31.60 0.001 9.05 2.22–36.86 0.002
Number of prior therapies (1 vs. ≥2) 0.66 0.21–2.08 0.479
NLR (<3.45 vs. ≥3.45) 2.98 0.89–10.03 0.078
PLR (<1.61 vs. ≥1.61) 2.27 0.68–7.59 0.185
CRP (<1 mg/dL vs. ≥1 mg/dL) 2.69 0.80–9.00 0.109

Abbreviations: RCC = renal cell carcinoma, HR = hazard ratio, CI = confidence interval, MSKCC = Memorial Sloan Kettering Cancer Center, NLR = neutrophil to lymphocyte ratio, PLR = platelet to lymphocyte ratio, CRP = C reactive protein.